Interview With Galina Selivanova

Professor Galina Selivanova (GS) heads a research group in the Department of Microbiology, Tumor and Cell Biology of the Karolinska Institute in Stockholm, one of Europe's leading medical schools and research institutes. Her work focuses on re-activating TP53 using small molecule drugs, some of which are beginning to emerge into clinical trials. She is generally acknowledged to be one of the world's leading researchers on TP53 as a medical target in oncology. She is interviewed here: http://www.tp53.co.uk/index.php/interview-galina-selivanova and what she has to say is generally optimistic, which is welcome given how optimism is in precious short supply when it comes to Li Fraumeni Syndrome